Clinical Trial ResultsSPRB reported disappointing Phase 2b CAHmelia-203 data in March 2024.
Drug Compliance50% of patients had less than 80% compliance.
Regulatory And Commercial RisksRisks include failure to show clinical impact in the Phase 2b trials of tildacerfont, inability to obtain timely regulatory approval, setbacks in other clinical development programs, slower-than-anticipated commercial uptake, and medium- to long-term dilution risk.